FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578819787> ?p ?o ?g. }

• W2578819787 abstract "Abstract Abstract 3068 Mantle cell lymphoma (MCL) has a poor long-term prognosis. Though autologous transplant prolongs survival, novel and mechanistically distinct therapies are needed to target residual, myeloablation-resistant tumor cells that result in relapse. Trials of CpG-based vaccines for low-grade lymphoma have shown induction of anti-tumor T cells and clinical responses [Brody J. et al, J Clin Oncol. 2010 Oct 1;28(28) :4324–32]. In a pre-clinical model, we developed the immunotransplant maneuver combining: 1) CpG-based vaccination, 2) harvest of vaccine-primed T cells, 3) myeloablation with stem cell rescue, and 4) T cell re-infusion. Immunotransplant amplifies the proportion of anti-tumor T cells by an order of magnitude and cures even bulky, systemic lymphoma burden [Brody J. et al, Blood. 2009 Jan 1;113(1) :85–94]. METHODS: We initiated a phase I/II study of immunotransplant for newly diagnosed MCL patients to test the hypothesis that immunotransplant will amplify anti-tumor T cells as in the pre-clinical model. Anti-tumor T cells are assessed by co-culturing autologous tumor with peripheral blood T cells and measuring their production of: IFNg, TNF, IL2, CD137, perforin and granzyme by multiplex surface and intracellular flow cytometry. A secondary endpoint is measurement of molecular residual disease (MRD) using both standard allele-specific oligonucleotide (ASO) qPCR as well as high-throughput sequencing (HTS) of the entire IgH repertoire. The study is powered to detect a 50% improvement in sustained molecular remission rate compared to recent trials of standard transplant [Pott C. et al, Blood 2010 Apr 22;115(16) :3215–23, Geisler C. et al, Blood 2008 Oct 1;112(7) :2687–93]. Using the same HTS technology, we have also initiated studies of the entire TCR β repertoire as an alternate approach of tracking the amplification of vaccine-induced T-cells. RESULTS: Accrual has been rapid with 25 patients enrolled in 22 months and 13 patients completing the complete protocol so far. Flow-cytometric immune response testing has demonstrated that immunotransplant amplifies the proportion of tumor-reactive T cells in 83% of patients thus far. Notably, we have observed some patients with primarily CD8 T cell responses, some with CD4 T cell responses, and some with a combination of the two. In some cases, tumor-reactive T cells have been tested for reactivity to autologous, non-malignant B cells and have demonstrated a significant proportion that are tumor-specific. TCR β repertoire sequencing has also demonstrated instances of significant clonal amplification after immunotransplantation, some exceeding three orders of magnitude. In extreme cases, these have yielded dominant clones comprising as much as 50% of a patient's entire peripheral blood T cell repertoire post-transplant. HTS of the IgH repertoire has been an effective measurement of MRD bypassing the assay individualization of ASO qPCR and has been shown to be more sensitive than conventional flow cytometry. CONCLUSIONS: Pre-clinically, amplification of anti-tumor T cells correlates with cure of even myeloablation-resistant disease. The reiteration of anti-tumor T cell amplification in our preliminary patient data raises the possibility that immunotransplant may improve clinical outcomes. Ongoing MRD testing should suggest whether certain patterns of T cell response –measured functionally per flow cytometry or clonally per HTS- correlate with clinical benefit and whether the cohort has a better-than-expected molecular remission rate. Disclosures: Moorhead: Sequenta, Inc.: Employment. Zheng:Sequenta, Inc.: Employment. Klinger:Sequenta, Inc.: Employment. Faham:Sequenta Inc: Employment, Equity Ownership. Advani:Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2578819787 created "2017-01-26" @default.
• W2578819787 creator A5002571777 @default.
• W2578819787 creator A5005492422 @default.
• W2578819787 creator A5012405884 @default.
• W2578819787 creator A5017559600 @default.
• W2578819787 creator A5017842436 @default.
• W2578819787 creator A5022565348 @default.
• W2578819787 creator A5028206166 @default.
• W2578819787 creator A5052061341 @default.
• W2578819787 creator A5054118827 @default.
• W2578819787 creator A5060314041 @default.
• W2578819787 creator A5064631593 @default.
• W2578819787 creator A5072352701 @default.
• W2578819787 creator A5077947210 @default.
• W2578819787 creator A5083342021 @default.
• W2578819787 date "2011-11-18" @default.
• W2578819787 modified "2023-09-27" @default.
• W2578819787 title "Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results" @default.
• W2578819787 doi "https://doi.org/10.1182/blood.v118.21.3068.3068" @default.
• W2578819787 hasPublicationYear "2011" @default.
• W2578819787 type Work @default.
• W2578819787 sameAs 2578819787 @default.
• W2578819787 citedByCount "0" @default.
• W2578819787 crossrefType "journal-article" @default.
• W2578819787 hasAuthorship W2578819787A5002571777 @default.
• W2578819787 hasAuthorship W2578819787A5005492422 @default.
• W2578819787 hasAuthorship W2578819787A5012405884 @default.
• W2578819787 hasAuthorship W2578819787A5017559600 @default.
• W2578819787 hasAuthorship W2578819787A5017842436 @default.
• W2578819787 hasAuthorship W2578819787A5022565348 @default.
• W2578819787 hasAuthorship W2578819787A5028206166 @default.
• W2578819787 hasAuthorship W2578819787A5052061341 @default.
• W2578819787 hasAuthorship W2578819787A5054118827 @default.
• W2578819787 hasAuthorship W2578819787A5060314041 @default.
• W2578819787 hasAuthorship W2578819787A5064631593 @default.
• W2578819787 hasAuthorship W2578819787A5072352701 @default.
• W2578819787 hasAuthorship W2578819787A5077947210 @default.
• W2578819787 hasAuthorship W2578819787A5083342021 @default.
• W2578819787 hasConcept C143998085 @default.
• W2578819787 hasConcept C203014093 @default.
• W2578819787 hasConcept C2777525834 @default.
• W2578819787 hasConcept C2779338263 @default.
• W2578819787 hasConcept C2779823535 @default.
• W2578819787 hasConcept C2780007613 @default.
• W2578819787 hasConcept C502942594 @default.
• W2578819787 hasConcept C71924100 @default.
• W2578819787 hasConceptScore W2578819787C143998085 @default.
• W2578819787 hasConceptScore W2578819787C203014093 @default.
• W2578819787 hasConceptScore W2578819787C2777525834 @default.
• W2578819787 hasConceptScore W2578819787C2779338263 @default.
• W2578819787 hasConceptScore W2578819787C2779823535 @default.
• W2578819787 hasConceptScore W2578819787C2780007613 @default.
• W2578819787 hasConceptScore W2578819787C502942594 @default.
• W2578819787 hasConceptScore W2578819787C71924100 @default.
• W2578819787 hasLocation W25788197871 @default.
• W2578819787 hasOpenAccess W2578819787 @default.
• W2578819787 hasPrimaryLocation W25788197871 @default.
• W2578819787 hasRelatedWork W1763981524 @default.
• W2578819787 hasRelatedWork W2001608280 @default.
• W2578819787 hasRelatedWork W2033172239 @default.
• W2578819787 hasRelatedWork W2047492993 @default.
• W2578819787 hasRelatedWork W2228689854 @default.
• W2578819787 hasRelatedWork W2491670743 @default.
• W2578819787 hasRelatedWork W2546583786 @default.
• W2578819787 hasRelatedWork W2554915744 @default.
• W2578819787 hasRelatedWork W2578298626 @default.
• W2578819787 hasRelatedWork W2595324905 @default.
• W2578819787 hasRelatedWork W2777405454 @default.
• W2578819787 hasRelatedWork W2979344655 @default.
• W2578819787 hasRelatedWork W2979620276 @default.
• W2578819787 hasRelatedWork W2987502937 @default.
• W2578819787 hasRelatedWork W2994062545 @default.
• W2578819787 hasRelatedWork W3028083786 @default.
• W2578819787 hasRelatedWork W3043487700 @default.
• W2578819787 hasRelatedWork W3097694581 @default.
• W2578819787 hasRelatedWork W3155467672 @default.
• W2578819787 hasRelatedWork W3187888740 @default.
• W2578819787 isParatext "false" @default.
• W2578819787 isRetracted "false" @default.
• W2578819787 magId "2578819787" @default.
• W2578819787 workType "article" @default.